Manages acute pain severe enough to require an intravenous opioid analgesic. Sold as Olinvyk. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Oliceridine (sold as Olinvyk), first approved Aug 7, 2020, with 0 new uses approved and 1 published complete response letter.
| Effects of Biased Opioid Agonists on Gastrointestinal Recovery After Gynecologic Laparoscopic SurgeryGynecologic Laparoscopic Surgery, Postoperative Gastrointestinal Dysfunction · Hainan Medical College | Phase 4 | Recruiting | Nov 9, 2026 |
| The Impact of Long-term High-risk Drinking on the Effective Dose of OsselidinSedation · Affiliated Hospital of Jiaxing University | Not applicable | Not yet recruiting | Oct 19, 2026 |
| Oliceridine-Propofol Dose for Gastroscope Insertion in Obese PatientsObesity, Gastrointestinal Endoscopy · Lu Yi | Phase 4 | Not yet recruiting | Aug 12, 2026 |
| Oliceridine Versus Sufentanil Analgesia for Postoperative Patients With Obstructive Sleep ApneaObstructive Sleep Apnea, Postoperative Analgesia · Peking University First Hospital | — | Not yet recruiting | Aug 10, 2026 |
| Oliceridine vs Sufentanil for Cough During Anesthesia InductionCough, Anesthesia · Shiyou Wei | Phase 4 | Recruiting | Jun 22, 2026 |
| Oliceridine for Gastrointestinal DysfunctionGastrointestinal Dysfunction · Beijing Tiantan Hospital | Not applicable | Not yet recruiting | Jun 16, 2026 |
| Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle SurgeryPONV, Cerebellopontine Angle Tumor · Xuanwu Hospital, Beijing | Not applicable | Recruiting | Mar 18, 2026 |
| Effect of Postoperative Analgesia of Oliceridine Fumarate for Gastrointestinal Function Recovery in Patients Undergoing Lumbar Spine SurgeryOliceridine Fumarate · Xijing Hospital | Not applicable | Recruiting | Dec 29, 2025 |
| Letter | Product | Now |
|---|---|---|
| Nov 2, 2018 | OliceridineClinical, Nonclinical, Product Quality | Approved |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA